

## Correction: Incidence and risk of regorafenib-induced hepatotoxicity

**Bin Zhao<sup>1</sup> and Hong Zhao<sup>1,2</sup>**

<sup>1</sup> The Second Affiliated Hospital and Yuying Children's Hospital, Wenzhou Medical University, Wenzhou, 325027, China

<sup>2</sup> Department of Medical Oncology, The Third Affiliated Hospital of Harbin Medical University, Harbin, 150081, China

**Published:** January 04, 2019

**Copyright:** Zhao et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**This article has been corrected:** The correct author affiliation information is given below:

**Hong Zhao<sup>1,2</sup>**

Original article: Oncotarget. 2017; 8:84102-84111. <https://doi.org/10.18632/oncotarget.21106>